Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study
Autore:
DellAgnello, G; Ceravolo, R; Nuti, A; Bellini, G; Piccinni, A; DAvino, C; DellOsso, L; Bonuccelli, U;
Indirizzi:
Univ Pisa, Dept Neurosci, I-56126 Pisa, Italy Univ Pisa Pisa Italy I-56126 iv Pisa, Dept Neurosci, I-56126 Pisa, Italy Univ Pisa, Dept Clin Neurol, I-56126 Pisa, Italy Univ Pisa Pisa Italy I-56126 Pisa, Dept Clin Neurol, I-56126 Pisa, Italy Univ Pisa, Dept Psychiat, I-56126 Pisa, Italy Univ Pisa Pisa Italy I-56126 iv Pisa, Dept Psychiat, I-56126 Pisa, Italy
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 4, volume: 24, anno: 2001,
pagine: 221 - 227
SICI:
0362-5664(200107/08)24:4<221:SDNWPD>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN SYNDROME; FLUOXETINE; DEPRESSION; ANTIDEPRESSANT; PAROXETINE; INHIBITOR; THERAPY; INVIVO;
Keywords:
Parkinson's disease; depression; serotonin selective reuptake inhibitors;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Bonuccelli, U Univ Pisa, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy Univ Pisa Via Roma 67 Pisa Italy I-56126 -56126 Pisa, Italy
Citazione:
G. Dell'Agnello et al., "SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study", CLIN NEUROP, 24(4), 2001, pp. 221-227

Abstract

Selective serotonin reuptake inhibitors (SSRIs) have been reported to be useful in the treatment of depression in patients with Parkinson's disease (PD). However, a few reports have suggested that SSRIs may worsen parkinsonian motor symptomatology and extrapyramidal side effects have been reported in depressed patients treated with SSRIs. So far, no prospective trial comparing the effects of different SSRIs in depressed patients with PD has beenperformed. The aim of the present study was to assess the effects of four SSRIs (citalopram, fluoxetine, fluvoxamine, and sertraline) on motor performance and their efficacy on depression in a group of patients with PD. Sixty-two consecutive nondemented, nonfluctuating, depressed patients with PD were included in four treatment groups (15 patiens received citalopram, 16 fluoxetine, 16 fluvoxamine, and 15 sertraline). The evaluation of extrapyramidal and depressive symptomatology was performed with use of the Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory, and Hamilton Depression Rating Scale at baseline and after 1, 3, and 6 months. Fifty-two patients completed the study. UPDRS scores were not significantly modified by the add-on therapy with each of the SSRIs Studied. A significant improvement in depressive symptoms from baseline to the end of the trial wasobtained with all SSRIs (Beck and Hamilton scores improving; p < 0.05 according to an analysis of variance). Our findings suggest that SSRIs do not significantly worsen extrapyramidal symptomatology and may ameliorate depression in patients with PD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 07:11:34